PROTEUS Trial at ASCO 2026: Perioperative Apalutamide Plus ADT in high-risk localized or locally advanced prostate cancer
oncodaily - PROTEUS trial, was presented during the ASCO 2026 Plenary Session by Mary-Ellen Taplin, MD, FASCO. The study evaluated one year of perioperative apalutamide plus androgen deprivation therapy in patients with […]
AI Summary: A perioperative strategy adding apalutamide to androgen‑deprivation therapy around radical prostatectomy shows improved outcomes for men with high‑risk or locally advanced prostate cancer, reducing metastasis and disease‑related death. Findings were highlighted and debated at ASCO sessions, prompting discussion about changing perioperative standards — and yes, surgeons are already updating their talking points.
- Industry, webinars and social media amplification of ASCO results (3)
- On-the-ground clinician reaction and emerging cN1 debate (3)
- PROTEUS trial: perioperative apalutamide reduces metastasis and death (3)
Industry, webinars and social media amplification of ASCO results
On-the-ground clinician reaction and emerging cN1 debate
PROTEUS trial: perioperative apalutamide reduces metastasis and death
Blog Post
PROTEUS (Phase III) — presented at the ASCO 2026 Plenary by Mary‑Ellen Taplin, MD — found that adding apalutamide to perioperative androgen‑deprivation therapy (given before and after radical prostatectomy, for about one year) in men with high‑risk localized or locally advanced prostate cancer increased major pathologic responses and reduced the risk of metastasis or disease‑related death, meeting both primary endpoints. The international trial (co‑led by Taplin and Adam Kibel, MD) has prompted plenary‑level discussion about changing perioperative practice — and surgeons are already updating their talking points. Sources: PROTEUS ASCO presentation and coverage (Medical Xpress, ESMO, OncoDaily).